UNTHSC gets $1.5 million to study possible glaucoma treatment

November 1, 2018

ByJan Jarvis

Dr Zode in lab
 
First, Gulab Zode, PhD, and his team of researchers discovered how a gene that causes glaucoma leads to the pathology in the eye. Then they found a drug to treat and cure a rare form of the blinding eye disease.

Now that same drug could one day be used to treat open angle glaucoma, the most common form of the disease.

Previous studies showed that the drug sodium-phenybutyrate plays an important role in reducing the elevated pressure that causes glaucoma, said Dr. Zode, Associate Professor of Pharmacology & Neuroscience.

“What we hope to show is that this drug can be used to not only treat a rare form of glaucoma, but cure all forms of the disease,” Dr. Zode said.

Dr. Zode recently received a $1.5 million grant from National Eye Institute to study how the drug can be used as a targeted treatment for open angle glaucoma. For many years, patients with glaucoma have been treated with drugs that reduce intraocular pressure but the actual cause of the disease has never been addressed.

If this drug proves effective, it could open the door to a cure for the second leading cause of irreversible blindness. The drug has been shown to be effective for the genetic form of the disease that affects about 2 million people under the age of 40 worldwide. But it is now being studied as a treatment for the more than 64 million people in the world who have open angle glaucoma.

In previous studies, researchers at the North Texas Eye Research Institutewere able to eliminate myocilin, a protein involved in both juvenile and adult-onset open-angle glaucoma, and lower intraocular pressure to prevent further damage to the eye.

Using the drug sodium 4-phenybutyrate, it is possible to target the ER stress pathway and correct the damage caused by glaucoma, Dr. Zode said.

“None of the treatments so far target the pathology of the disease,” he said. “But this drug can target the pathway that causes the damage to the eye.”

The Food and Drug Administration has already approved the drug for urea cycle disorders, ahereditary metabolic condition caused by a deficiency of one of the enzymes in the urea cycle responsible for removing ammonia from the bloodstream.

“Our goal is to take the studies being done now and take them to a clinic to be tested in patients,” Dr. Zode said.

Hiv Fc
For pharmacy class, a lesson in living with HIV

By Jan Jarvis   Shelia Neal can’t recall much of what happened on the day she learned she was HIV positive because of the sheer shock of it all. But one thing stands out. “Until then, I had never had a doctor bend down and look at me eye-to-eye,” she said. “But she did, and ...Read more

Dec 12, 2018

Mathis Fc
A new dean for Graduate School of Biomedical Sciences

By Jan Jarvis   Michael Mathis, PhD, sees plenty of similarities between his current job at Louisiana State University’s School of Veterinary Medicine, and his future one as dean of the Graduate School of Biomedical Sciences at UNT Health Science Center. “A medical school and a vet...Read more

Dec 11, 2018

Maria Fc
Domestic violence’s painful legacy

By Sally Crocker In the fall of 1984, Maria Guadalupe Almaguer was murdered by her estranged husband, David Gonzales. The couple had been separated for two years following a rocky, abusive relationship, and Maria had been saving for a divorce. She had just been promoted at work, and thi...Read more

Dec 5, 2018

Jann Fc
Professor honored by American College of Clinical Pharmacology

By Jan Jarvis   For more than 30 years, Michael Jann, PharmD, has collaborated with physicians, scientists, pharmacists and other health care professionals with the goal of improving patient care. His outstanding achievements and contributions were recently recognized by the American C...Read more

Nov 29, 2018